

United States Patent [19]

Billiar et al.

[11] Patent Number:

5,658,565

Date of Patent: [45]

Aug. 19, 1997

Chin, et al., 1992, Inactivation of Endothelial Derived Relaxing Factor by Oxidized Lipoproteins, J. Clin. Invest, 89:10-18.

Chester, et al., 1990, Low Basal and Stimulted Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries, Lancet 336: 897-900.

Wilson, et al., 1989, Implantation of Vascular Grafts Lines with Genetically Modified Endothelial Cells, Science 244: 1344-1346.

Ignarro, et al., 1987, Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein is Nitric Oxide, PNAS 84: 9265-9269.

Radomski et al., 1987, The Anti-Aggregating Properties of Vascular Endothelium: Interactions Between Prostacyclin and Nitric Oxide, Br. J. Pharmac. 92: 639-646.

Nunokawa and Tanaka, 1992, Interferon-Gamma Inhibits Proliferation of Rat Vascular Smooth Muscle Cells by Nitric Oxide Generation, Biochem. Biophys. Res. Comm. 188:

Werner-Felmayer, et al., 1990, Tetrahydrobiopterin-Dependent Formation of Nitrite and Nitrate in Murine Fibroblasts, J. Exp. Med. 172: 1599-1607.

Moncada, et al., 1991, Nitric Oxide: Physiology, Pathophysiology and, Pharmacology, Pharmacological Reviews 43: 109-142.

Nabel, et al., 1989, Recombinant Gene Expression In Vivo Within Endothelial Cells of the Arterial Wall, Science 244: 1342-1344.

Zwiebel, et al., 1989, High-Level Recombinant Gene Expression in Rabbit Endothelial Cells Transduced by Retroviral Vectors, Science 243: 220-222.

Nabel, et al., 1990, Site-Specific Gene Expression In Vivo by Direct Gene Transfer into the Artierial Wall, Science 249:1285-1288.

Nussler, et al., 1992, Stimulation of Nitric Oxide in Human Hepatocytes by Cytokines, Faseb J., 6 (5): A1834 (#5200). Draiper, et al., 1991, L-arginine-derived Nitric Oxide and the Cell-Mediated Immune Response, Res. Immunol. 142: 553-602.

Janssens, et al., 1992, Cloning and Expression of a cDNA Encoding Human Endothelial-Derived Relaxing Factor/Nitric Oxide Synthase, J. Biol. Chem. 267: 14519-14522.

(List continued on next page.)

Primary Examiner—Christopher S.F. Low Attorney, Agent, or Firm-Leydig, Voit & Mayer, Ltd.

[57] ABSTRACT

The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed invention, iNOS-directed gene therapy involves specific targeting of a DNA sequence encoding a protein or protein fragment with iNOS biological activity for treating vascular diseases and disorders, antitumor applications and in response to certain microbial infections.

40 Claims, 5 Drawing Sheets

[54] INDUCIBLE NITRIC OXIDE SYNTHASE GENE FOR TREATMENT OF DISEASE [75] Inventors: Timothy R. Billiar; Edith Tzeng, both Richard L. Simmons, both of Pittsburgh, Pa. [73] Assignee: University of Pittsburgh of the Commonwealth System of Higher Education, Pittsburgh, Pa. [21] Appl. No.: 265,046 [22] Filed: Jun. 24, 1994

[56] References Cited

U.S. PATENT DOCUMENTS

5,132,407	7/1992	Shuehr et al 530/395
5,252,479	10/1993	Srivastava 435/320.1
5,328,470	7/1994	Nabel et al 604/101
5,428,070	6/1995	Cooke et al 514/557

FOREIGN PATENT DOCUMENTS

92/07943 5/1992 WIPO.

OTHER PUBLICATIONS

Geller, et al., 1993, Molecular Cloning and Expression of Inducible Nitric Oxide Synthase from Human Hepatocytes, PNAS 90: 3491-3495.

Nussler, et al., 1992, Stimulation of the Nitric Oxide Synthase Pathway in Human Hepatocytes by Cytokines and Endotoxins, J. Exp. Med. 176: 261-264.

Lowenstein, et al., 1992, Cloned and Expressed Macrophage Nitric Oxide Synthase Contrasts with the Brain Enzyme, PNAS 89: 6711-6715.

Xie, et al., 1992, Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages, Science 256: 225-228.

Lyons, et al., 1992, Molecular Cloning and Functional Expression of an Inducible Nitric Oxide Synthase from a Murine Macrophage Cell Line, J. Biol. Chem. 267: 6370-6374.

von der Leven, et al., 1994, In Vivo Gene Transfer to Prevent Neointima Hyperplasia after Vascular Injury: Effect of Overexpression of Constitutive Nitric Oxide Synthase, Faseb J. 8:A802 (#4651).

Bucala, et al., 1991, Advanced Glycosylation Products Quench Nitric Oxide and Mediate Defective Endothelium-Dependent Vasodilatatin in Experimental Diabetes, J. Clin. Invest. 87: 432-438.

of Pittsburgh, Pa.: Andreas K. Nüssler, Neu-Ulm, Germany; David A. Geller:

[51] Int. Cl.⁶ A61K 48/00 **U.S. Cl.** **424/93.21**; 424/93.2; 424/93.1; 514/44; 435/189; 435/191; 435/320.1; 435/172.3; 435/235.1; 536/23.1; 536/23.2; 536/23.5; 935/60; 935/22; 935/32; 935/9

435/320.1, 235.1; 514/44; 424/423, 93.1, 93.2; 536/23.1, 23.2, 23.5; 935/9, 10, 14, 22, 23, 32